Basic Info.
Model NO.
BB033
Resource
Natural
Smell
Addible
Appearance
Colorful Capsule
Density Cfu
150b/G
Net Content
1,000 Grains
Transport Package
Plastic and Al Foil Bag
Specification
TBC
Trademark
BIODEP
Origin
China
HS Code
21069090
Production Capacity
10, 000bags/M
Product Description
Biodep Strain Number
Bifidobacterium Breve BB033.
Description
Bifidobacterium Breve BB033 was isolated from infant body. B. breve
BB033 administered in combination with prebiotics or other Probiotics and
standard therapy has shown some beneficial effect. It is a constituent in the
therapeutic, nutritional treatment and is used to treat ulcerative colitis. And
it has been used to adjust immunity.
The use of microorganisms to treat or prevent targeted diseases was conceived at the end of the last millennium. This concept has rapidly evolved giving rise to a new branch of applied microbiology known as "therapeutic microbiology". Since human organisms and gut microbiota establish an intimate symbiotic relationship that is fundamental for the maintenance of the host's health, the administration of beneficial microorganisms may represent a key determinant of the general health status and diseases susceptibility. The choice for the most suitable species for a certain pathology requires extensive studies, both in vitro and in vivo. Moreover, it is known that strains belonging to the same species may express different functions in vivo. It has also been demonstrated that blending different microbial strains, species or even genera, may lead to a final effect that is not predicted by results from using each single microorganism. Several Bifidobacterium species are largely used as probiotics for their capability of reaching and colonizing the gastrointestinal tract and their documented history of safety. Among them, Bifidobacterium breve, originally isolated from infant faeces, represents one of the most used probiotics in infants. The multiple studies in which B. breve strains have been successfully used in diseased humans, especially children and newborns, witness the potentiality of strains belonging to this species for the prevention or treatment of human diseases. The aim of this review is to show the various applications of B. breve for preventing and treating paediatric diseases starting from in vitro and mice model assessment of efficacy to the clinical use. To the best of our knowledge, this work represents the first collection of works focused on the application in paediatrics of strains belonging to the B. breve species and is aimed to shed light on the role of this Bifidobacterium species in the scenario of "therapeutic microbiology." Moreover, this paper explores the effectiveness of B. breve used both as a single strain and combined with other microorganisms with a final short outcome of its application in adulthood
Storage
Keep at 5-15DC and out of sunlight, keep away from children.
More;
Bifidobacterium Breve BB033.
Description
Bifidobacterium Breve BB033 was isolated from infant body. B. breve
BB033 administered in combination with prebiotics or other Probiotics and
standard therapy has shown some beneficial effect. It is a constituent in the
therapeutic, nutritional treatment and is used to treat ulcerative colitis. And
it has been used to adjust immunity.
The use of microorganisms to treat or prevent targeted diseases was conceived at the end of the last millennium. This concept has rapidly evolved giving rise to a new branch of applied microbiology known as "therapeutic microbiology". Since human organisms and gut microbiota establish an intimate symbiotic relationship that is fundamental for the maintenance of the host's health, the administration of beneficial microorganisms may represent a key determinant of the general health status and diseases susceptibility. The choice for the most suitable species for a certain pathology requires extensive studies, both in vitro and in vivo. Moreover, it is known that strains belonging to the same species may express different functions in vivo. It has also been demonstrated that blending different microbial strains, species or even genera, may lead to a final effect that is not predicted by results from using each single microorganism. Several Bifidobacterium species are largely used as probiotics for their capability of reaching and colonizing the gastrointestinal tract and their documented history of safety. Among them, Bifidobacterium breve, originally isolated from infant faeces, represents one of the most used probiotics in infants. The multiple studies in which B. breve strains have been successfully used in diseased humans, especially children and newborns, witness the potentiality of strains belonging to this species for the prevention or treatment of human diseases. The aim of this review is to show the various applications of B. breve for preventing and treating paediatric diseases starting from in vitro and mice model assessment of efficacy to the clinical use. To the best of our knowledge, this work represents the first collection of works focused on the application in paediatrics of strains belonging to the B. breve species and is aimed to shed light on the role of this Bifidobacterium species in the scenario of "therapeutic microbiology." Moreover, this paper explores the effectiveness of B. breve used both as a single strain and combined with other microorganisms with a final short outcome of its application in adulthood
Regulation
Legislation can be varied by country when it comes to specific dosage and potential health claims of each strain.
Our regulatory team can help and advise you as to the appropriate individual markets permit. we are committed to deliver expert advice and practical solutions in order to optimize your company's success.
Storage
Keep at 5-15DC and out of sunlight, keep away from children.
More;
| LIST OF STRAINS | |||
| Probiotics | Strain Number | Type(CFU/g) | |
| Lactiplantibacillus plantarum | Lp3a | 5-500B | |
| Lacticaseibacillus rhamnosus | LR05 | 5-400B | |
| Lacticaseibacillus casei | LC11 | 5-400B | |
| Lacticaseibacillus paracasei | LPC45 | 5-400B | |
| Lactobacillus fermentum | LF021 | 5-300B | |
| Lactobacillus salivarius | LS01 | 5-100B | |
| Lactobacillus reuteri | LR06 | 5-200B | |
| Lactobacillus acidophi/us | LA16 | 5-200B | |
| Lactobacillus helveticus | LH030/LZ-R-5 | 5-200B | |
| Lactobacillus crispatus | LCP051 | 5-100B | |
| Lactobacillus gasseri | LG021/LG019 | 5-200B | |
| Lactobacillus johnsonii | LJ10 | 5-100B | |
| Lactobacillus delbrueckii subsp. bulgaricus | LB45 | 5-20B | |
| Bifidobacterium animalis subsp. lactis | Bla019 | 5-400B | |
| Bifidobacterium animalis subsp. animalis | BA023 | 5-500B | |
| Bifidobacterium breve | BB033 | 5-200B | |
| Bifidobacterium longum subsp. longum | BL5b | 5-100B | |
| Bidobacterium longum subsp. infantis | BI08 | 5-50B | |
| Bifidobacterium bifidum | BMC31 | 5-200B | |
| Bifidobacterium adolesentis | BAA021 | 5-100B | |
| Streptococcus salivarius subsp. thermophilus | ST076 | 5-300B | |
| Pediococcus pentosaceus | PP016 | 5-300B | |
| Pediococcus acidolactici | PAL31 | 5-400B | |
| Leuconostoc mesenteroides subsp. mesenteroides | LCM020 | 5-200B | |
| Weizmannia coagulans | BC01 | 5-100B | |
| Akkermansia muciniphila | AMP018 | 5-200B | |
